MedTrace Logo

Effectiveness of an Intervention Using Observation/Action Therapy Among Patients With Mild Cognitive Impairment

NCT05934344 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2023-07-06

No results posted yet for this study

Summary

Mild cognitive impairment (MCI) is a transitional state between normal aging and early dementia, characterized by memory deficits without functional impairment. Cognitive decline prevalence is increasing in older adults, impacting independence and quality of life. Motor dysfunctions, often overlooked in MCI, contribute to these limitations. Action Observation Therapy (AOT), a rehabilitation approach involving observing and imitating motor gestures, promotes brain plasticity through the mirror neuron system. While AOT has shown effectiveness in various populations, its application in MCI is understudied. This study aims to investigate the effects of AOT on cognition, upper and lower limb function, daily activities, gait, and balance in MCI patients. It also compares outcomes when patients observe therapists or MCI individuals with similar characteristics. Primary objectives include comparing AOT efficacy between these groups and a control group. Secondary objectives focus on upper limb functionality, daily activities, balance, cognition, and gait.

Conditions

Interventions

OTHER

Action observation training

The activities proposed will be based on items from the FMA scale (Voluntary movement within synergies, voluntary movement mixing synergies, voluntary movement with little or no synergy, grip, coordination/speed, passive joint movement), and the exercises for the lower limbs will be designed by the authors of the study, based on Vivifrail (32), a multicomponent physical training program for the prevention of deconditioning and falls in older adults. These exercises will be progressive each week, focusing on strengthening, balance, and functional exercises to improve gait. The sessions will last between 20 and 30 minutes, with a frequency of three days per week. The intervention will last for 5 weeks.

Sponsors & Collaborators

  • Universidad Europea de Madrid

    lead OTHER

Principal Investigators

  • Cecilia Estrada Barranco, PhD · Universidad Europea de Madrid

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
65 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-04-01
Primary Completion
2023-06-30
Completion
2023-07-20

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05934344 on ClinicalTrials.gov